| Ticker Details |
Boston Scientific Corp.
Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Health Care Equipment and Supplies |
| Market Cap: |
$91.07B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.34 | 1.22%
|
| Avg Daily Range (30 D): |
$0.90 | 1.30%
|
| Avg Daily Range (90 D): |
$0.95 | 1.16%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
9.93M |
| Avg Daily Volume (30 D): |
12.4M |
| Avg Daily Volume (90 D): |
11.66M |
| Trade Size |
| Avg Trade Size (Sh.): |
244 |
| Avg Trade Size (Sh.) (30 D): |
90 |
| Avg Trade Size (Sh.) (90 D): |
88 |
| Institutional Trades |
| Total Institutional Trades: |
107,001 |
| Avg Institutional Trade: |
$3.4M |
| Avg Institutional Trade (30 D): |
$6.95M |
| Avg Institutional Trade (90 D): |
$8.25M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
18 |
| Market Closing Trades |
| Avg Closing Trade: |
$29.47M |
| Avg Closing Trade (30 D): |
$146.43M |
| Avg Closing Trade (90 D): |
$148.42M |
| Avg Closing Volume: |
717.49K |
|
|
| News |
Apr 9, 2026 @ 6:53 PM
ROSEN, A RANKED AND LEADING FIRM, Encourages Bosto...
Source: Rosen Law Firm
|
Apr 5, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Boston Sci...
Source: Bronstein, Gewirtz & Grossman Llc
|
Apr 5, 2026 @ 12:46 PM
Nike, Boston Scientific, And Sysco Are Among Top 1...
Source: Nabaparna Bhattacharya
|
Apr 4, 2026 @ 1:56 AM
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages B...
Source: Rosen Law Firm
|
Apr 1, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Boston Sci...
Source: Bronstein, Gewirtz & Grossman Llc
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$1.96
|
$.46
|
$1.96
|
|
Diluted EPS
|
$1.94
|
$.45
|
$1.94
|
|
Revenue
|
$20.07B
|
$5.29B
|
$20.07B
|
|
Gross Profit
|
$13.85B
|
$3.68B
|
$13.85B
|
|
Net Income / Loss
|
$2.89B
|
$670M
|
$2.89B
|
|
Operating Income / Loss
|
$3.61B
|
$825M
|
$3.61B
|
|
Cost of Revenue
|
$6.22B
|
$1.61B
|
$6.22B
|
|
Net Cash Flow
|
$1.54B
|
$671M
|
$1.54B
|
|
PE Ratio
|
31.80
|
|
|
|
|
|
